Mycophenolate mofetil alleviates pulmonary fibrosis in mice

Cao Shu,Li Shaolin,Lan Xi,Wang Yong,Zou Dongling,Zang Chunbao,Wang Ying
DOI: https://doi.org/10.16016/j.1000-5404.2012.24.031
2012-01-01
Abstract:Objective To investigate the possible underlying mechanism of mycophenolate mofetil(MMF) in treating bleomycin(BLM)-induced pulmonary fibrosis in mice.Methods Thirty-six C57BL/6 mice were randomly divided into 6 groups(n=6 for each group),including normal control group,MMF control group,BLM model group and MMF treatment groups at low,media and high doses.In 1 d after BLM(6 mg/kg) was intratracheally instilled to the mice from BLM model group and MMF treatment groups,MMF was given orally in the later groups at a dose of 20,60 and 100 mg/kg respectively once per day for 2 weeks.All mice were killed after the treatment,and their lung tissues were collected.Pulmonary fibrosis was evaluated by Ashcroft score after HE and masson trichrome staining.The expression of collagen 1(COLA1) and COLA2 at mRNA levels was determined by RT-PCR.TGF-β1 protein was analyzed by immunohistochemistry.Results BLM-induced pulmonary fibrosis model was successfully constructed.High dose MMF treatment resulted in significant attenuated fibrosis,lower expression of COLA and COLA2 at mRNA level,and decreased TGF-β1 protein(P<0.01) when compared with BLM group.No statistic difference was found between the other MMF treatment groups and BLM model groups,MMF control group and normal control group(P>0.05).Conclusion MMF significantly attenuates BLM-induce pulmonary fibrosis in mice,which may be due to its inhibition of TGF-β1 expression.
What problem does this paper attempt to address?